175 related articles for article (PubMed ID: 10690534)
41. Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancer.
Sánchez-Céspedes M; Rosell R; Pifarré A; López-Cabrerizo MP; Barnadas A; Sánchez JJ; Lorenzo JC; Abad A; Monzó M; Navas-Palacios JJ
Clin Cancer Res; 1997 Jul; 3(7):1229-35. PubMed ID: 9815804
[TBL] [Abstract][Full Text] [Related]
42. Artificial neural networks and logistic regression as tools for prediction of survival in patients with Stages I and II non-small cell lung cancer.
Marchevsky AM; Patel S; Wiley KJ; Stephenson MA; Gondo M; Brown RW; Yi ES; Benedict WF; Anton RC; Cagle PT
Mod Pathol; 1998 Jul; 11(7):618-25. PubMed ID: 9688182
[TBL] [Abstract][Full Text] [Related]
43. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer.
Takahashi T; Sonobe M; Menju T; Nakayama E; Mino N; Iwakiri S; Nagai S; Sato K; Miyahara R; Okubo K; Hirata T; Date H; Wada H
J Surg Oncol; 2010 May; 101(6):500-6. PubMed ID: 20213688
[TBL] [Abstract][Full Text] [Related]
44. [P53 and P16 gene mutations in non-small cell lung cancer].
Jassem E; Ramlau R; Dziadziuszko R; Szymanowska A; Jakóbkiewicz J; Lamperska K; Kobierska G; Skokowski J; Dyszkiewicz W; Mackiewicz A; Zylicz M; Jassem J
Pneumonol Alergol Pol; 2002; 70(1-2):64-70. PubMed ID: 12148179
[TBL] [Abstract][Full Text] [Related]
45. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.
Marchetti A; Buttitta F; Merlo G; Diella F; Pellegrini S; Pepe S; Macchiarini P; Chella A; Angeletti CA; Callahan R
Cancer Res; 1993 Jun; 53(12):2846-51. PubMed ID: 8389245
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
47. [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():345-52. PubMed ID: 9369906
[TBL] [Abstract][Full Text] [Related]
48. [Prognostic value of heterozygosity loss in chromosome 3p in non-microcytic bronchogenic carcinoma].
Maestro ML; Izquierdo L; Sánchez-Pernaute A; Sanz Casla MT; González S; Torres A; del Barco V; Gómez A; Pérez Aguirre E; Balibrea JL
Med Clin (Barc); 1999 Apr; 112(14):527-9. PubMed ID: 10363238
[TBL] [Abstract][Full Text] [Related]
49. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
Chevillard S; Lebeau J; Pouillart P; de Toma C; Beldjord C; Asselain B; Klijanienko J; Fourquet A; Magdelénat H; Vielh P
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2471-8. PubMed ID: 9815649
[TBL] [Abstract][Full Text] [Related]
50. Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer.
Wang YC; Chen CY; Wang HJ; Chen SK; Chang YY; Lin P
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):402-10. PubMed ID: 10418172
[TBL] [Abstract][Full Text] [Related]
51. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.
Mitsudomi T; Oyama T; Kusano T; Osaki T; Nakanishi R; Shirakusa T
J Natl Cancer Inst; 1993 Dec; 85(24):2018-23. PubMed ID: 8246288
[TBL] [Abstract][Full Text] [Related]
52. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
53. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients.
Kondo K; Tsuzuki H; Sasa M; Sumitomo M; Uyama T; Monden Y
J Surg Oncol; 1996 Jan; 61(1):20-6. PubMed ID: 8544455
[TBL] [Abstract][Full Text] [Related]
54. [Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer].
Szymanowska A; Jassem E; Dziadziuszko R; Skrzypski M; Kobierska-Gulida G; Holm K; Borg A; Rzyman W; Limon J; Jassem J
Pneumonol Alergol Pol; 2005; 73(3):264-9. PubMed ID: 16989164
[TBL] [Abstract][Full Text] [Related]
55. p53 gene mutations in non-small cell lung cancer from Thai patients.
Petmitr S; Makthiengtrong S; Sutinont P; Migasena P
J Med Assoc Thai; 1999 Mar; 82(3):250-5. PubMed ID: 10410479
[TBL] [Abstract][Full Text] [Related]
56. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
57. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis.
Sliutz G; Schmidt W; Tempfer C; Speiser P; Gitsch G; Eder S; Schneeberger C; Kainz C; Zeillinger R
Gynecol Oncol; 1997 Jan; 64(1):93-8. PubMed ID: 8995554
[TBL] [Abstract][Full Text] [Related]
58. A five-gene signature and clinical outcome in non-small-cell lung cancer.
Chen HY; Yu SL; Chen CH; Chang GC; Chen CY; Yuan A; Cheng CL; Wang CH; Terng HJ; Kao SF; Chan WK; Li HN; Liu CC; Singh S; Chen WJ; Chen JJ; Yang PC
N Engl J Med; 2007 Jan; 356(1):11-20. PubMed ID: 17202451
[TBL] [Abstract][Full Text] [Related]
59. [Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance].
Mitsudomi T; Oyama T; Gazdar AF; Minna JD; Okabayashi K; Shirakusa T
Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):944-7. PubMed ID: 1361656
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
